

# Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

https://marketpublishers.com/r/TDD7B4CA6E2CEN.html

Date: September 2022 Pages: 359 Price: US\$ 2,500.00 (Single User License) ID: TDD7B4CA6E2CEN

### **Abstracts**

Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Drugs In Development, 2022, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.



The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 16, 7, 2, 61, 44 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 6, 8, 39 and 34 molecules, respectively.

Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.



The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)

### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand



business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



### Contents

Introduction
Global Markets Direct Report Coverage
Tuberculosis - Overview
Tuberculosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tuberculosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tuberculosis - Companies Involved in Therapeutics Development
Tuberculosis - Drug Profiles
Tuberculosis - Dormant Projects
Tuberculosis - Discontinued Products
Tuberculosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



## **List Of Tables**

#### LIST OF TABLES

Number of Products under Development for Tuberculosis, 2022 Number of Products under Development by Companies, 2022 Number of Products under Development by Universities/Institutes, 2022 Products under Development by Companies, 2022 Products under Development by Universities/Institutes, 2022 Number of Products by Stage and Target, 2022 Number of Products by Stage and Target, 2022 (Contd..1) Number of Products by Stage and Target, 2022 (Contd..2) Number of Products by Stage and Mechanism of Action, 2022 Number of Products by Stage and Mechanism of Action, 2022 (Contd..1) Number of Products by Stage and Mechanism of Action, 2022 (Contd..2) Number of Products by Stage and Mechanism of Action, 2022 (Contd..2) Number of Products by Stage and Mechanism of Action, 2022 (Contd..2) Number of Products by Stage and Mechanism of Action, 2022 (Contd..2) Number of Products by Stage and Mechanism of Action, 2022 (Contd..2) Number of Products by Stage and Mechanism of Action, 2022 (Contd..2) Number of Products by Stage and Mechanism of Action, 2022 (Contd..2) Number of Products by Stage and Mechanism of Action, 2022 (Contd..2) Number of Products by Stage and Molecule Type, 2022 Tuberculosis - Dormant Projects, 2022 Tuberculosis - Discontinued Products, 2022



# **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development for Tuberculosis, 2022 Number of Products under Development by Companies, 2022 Number of Products under Development by Universities/Institutes, 2022 Number of Products by Top 10 Targets, 2022 Number of Products by Stage and Top 10 Targets, 2022 Number of Products by Top 10 Mechanism of Actions, 2022 Number of Products by Stage and Top 10 Mechanism of Actions, 2022 Number of Products by Top 10 Routes of Administration, 2022 Number of Products by Stage and Top 10 Routes of Administration, 2022 Number of Products by Stage and Top 10 Routes of Administration, 2022 Number of Products by Top 10 Molecule Types, 2022 Number of Products by Stage and Top 10 Molecule Types, 2022



### I would like to order

Product name: Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: https://marketpublishers.com/r/TDD7B4CA6E2CEN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/TDD7B4CA6E2CEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update